Photo by Pixabay on <a href="https://www.pexels.com/photo/20-mg-label-blister-pack-208512/" rel="nofollow">Pexels.com</a>
Akums Drugs and Pharmaceuticals, a prominent player in the pharmaceutical contract development and manufacturing (CDMO) segment, has successfully raised ₹828.78 crore from anchor investors ahead of its much-anticipated Initial Public Offering (IPO). This strong investor interest is a positive indicator for the upcoming public issue.
The company plans to utilize the proceeds from the IPO to repay and prepay outstanding borrowings, bolster working capital, and explore potential inorganic growth opportunities through acquisitions. Akums Drugs and Pharma has established itself as a leading CDMO in India, catering to a diverse clientele with a wide range of pharmaceutical products.
The IPO is scheduled to open for subscription on July 30 and close on August 1, 2024. The price band for the issue has been fixed at ₹646 to ₹679 per share. Investors are eagerly awaiting the opportunity to participate in the growth story of this promising pharmaceutical company.
